Maze Therapeutics’ (MAZE) “Buy” Rating Reiterated at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE) in a research report sent to investors on Wednesday morning,Benzinga reports. Guggenheim currently has a $19.00 target price on the stock.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set an “overweight” rating and a $30.00 target price on the stock. Leerink Partnrs upgraded Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, Leerink Partners assumed coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set an “outperform” rating and a $28.00 price objective on the stock. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Stock Down 2.7 %

MAZE opened at $9.07 on Wednesday. Maze Therapeutics has a 12 month low of $8.33 and a 12 month high of $17.00.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Monday, March 31st. The company reported ($18.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.60) by ($10.72).

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.